Exploration of the MUC5B promoter variant and ILD risk in patients with autoimmune myositis

Respiratory Medicine

Volumn 130, Issue , 2017, Pages 52-54

  Johnson, Cheilonda ^a   Rosen, Paul ^b   Lloyd, Thomas ^a   Horton, Maureen ^a   Christopher Stine, Lisa ^a   Oddis, Chester V ^c   Mammen, Andrew L ^a,d   Danoff, Sonye K ^a  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PRINCETON UNIVERSITY   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^d NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES   (United States)

Author keywords

Dermatomyositis; Interstitial lung diseases; Mucin 5B; Polymyositis; Single nucleotide polymorphism

Indexed keywords

MUCIN 5B; MUC5B PROTEIN, HUMAN;

ARTICLE; AUTOIMMUNE DISEASE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ASSOCIATION; GENE FREQUENCY; GENETIC ASSOCIATION; HUMAN; INTERSTITIAL LUNG DISEASE; INTERSTITIAL PNEUMONIA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK; RISK ASSESSMENT; CAUCASIAN; CHROMOSOME 11; COMPARATIVE STUDY; DERMATOMYOSITIS; FIBROSING ALVEOLITIS; GENETICS; IMMUNOLOGY; MYOSITIS; SINGLE NUCLEOTIDE POLYMORPHISM;

CHROMOSOMES, HUMAN, PAIR 11; DERMATOMYOSITIS; EUROPEAN CONTINENTAL ANCESTRY GROUP; GENE FREQUENCY; HUMANS; IDIOPATHIC INTERSTITIAL PNEUMONIAS; IDIOPATHIC PULMONARY FIBROSIS; LUNG DISEASES, INTERSTITIAL; MUCIN-5B; MYOSITIS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROMOTER REGIONS, GENETIC; RISK;

EID: 85025119799     PISSN: 09546111     EISSN: 15323064     Source Type: Journal    
DOI: 10.1016/j.rmed.2017.07.010     Document Type: Article

References (17)

1. Mimori, T., Nakashima, R., Hosono, Y., Interstitial lung disease in myositis: clinical subsets, biomarkers, and treatment. Curr. Rheumatol. Rep. 14:3 (2012 June), 264–274.
2. Solomon, J., Swigris, J.J., Brown, K.K., Myositis-related interstitial lung disease and antisynthetase syndrome. J. Bras. Pneumol. Publicacao Of. Soc. Bras. Pneumol. Tisilogia 37 (2011), 100–109.
3. Johnson, C., Pinal-Fernandez, I., Parikh, R., et al. Assessment of mortality in autoimmune myositis with and without associated interstitial lung disease. Lung 194:5 (2016 October), 733–737.
4. Nemery, B., Bast, A., Behr, J., et al. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur. Respir. J. Suppl. 32 (2001), 30s–42s.
5. Rosas, I.O., Kaminski, N., When it comes to genes–IPF or NSIP, familial or sporadic–they're all the same. Am. J. Respir. Crit. Care Med. 175 (2007), 5–6.
6. Seibold, M.A., Wise, A.L., Speer, M.C., et al. A common MUC5B promoter polymorphism and pulmonary fibrosis. N. Engl. J. Med. 364 (2011), 1503–1512.
7. Zhang, Y., Noth, I., Garcia, J.G., Kaminski, N., A variant in the promoter of MUC5B and idiopathic pulmonary fibrosis. N. Engl. J. Med. 364 (2011), 1576–1577.
8. Peljto, A.L., Steele, M.P., Fingerlin, T.E., et al. The pulmonary fibrosis-associated MUC5B promoter polymorphism does not influence the development of interstitial pneumonia in systemic sclerosis. Chest 142:6 (2012 Dec), 1584–1588.
9. Borie, R., Crestani, B., Dieude, P., et al. The MUC5B variant is associated with idiopathic pulmonary fibrosis but not with systemic sclerosis interstitial lung disease in the European Caucasian population. PLoS One, 8, 2013, e70621.
10. Stock, C.J., Sato, H., Fonseca, C., et al. Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax 68 (2013), 436–441.
11. American thoracic society/european respiratory society international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. This joint statement of the American thoracic society (ATS), and the european respiratory society (ERS) was adopted by the ATS board of directors, June 2001 and by the ERS executive committee, June 2001. Am. J. Respir. Crit. Care Med. 165 (2002), 277–304.
12. Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (second of two parts). N. Engl. J. Med. 292 (1975), 403–407.
13. Bohan, A., Peter, J.B., Polymyositis and dermatomyositis (first of two parts). N. Engl. J. Med. 292 (1975), 344–347.
14. A genome-wide search for asthma susceptibility loci in ethnically diverse populations. The Collaborative Study on the Genetics of Asthma (CSGA) Nat. Genet. 15 (1997), 389–392.
15. Database of Single Nucleotide Polymorphisms (dbSNP), 2012 Accessed 25 April, 2012, at http://www.ncbi.nlm.nih.gov/SNP/.
16. Purcell, S., Neale, B., Todd-Brown, K., et al. PLINK: a tool set for whole-genome association and population-based linkage analyses. Am. J. Hum. Genet. 81 (2007), 559–575.
17. Hirano, C., Ohshimo, S., Horimasu, Y., et al. FAM13A polymorphism as a prognostic factor in patients with idiopathic pulmonary fibrosis. Respir. Med. 123 (2017), 105–109.